BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20308630)

  • 1. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
    Lu H; Wagner WM; Gad E; Yang Y; Duan H; Amon LM; Van Denend N; Larson ER; Chang A; Tufvesson H; Disis ML
    J Immunol; 2010 May; 184(9):5360-7. PubMed ID: 20308630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
    Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
    Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
    J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
    Ito H; Ando T; Arioka Y; Saito K; Seishima M
    Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
    Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
    Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
    Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
    J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways.
    Duechs MJ; Hahn C; Benediktus E; Werner-Klein M; Braun A; Hoymann HG; Gantner F; Erb KJ
    Pulm Pharmacol Ther; 2011 Apr; 24(2):203-14. PubMed ID: 21195789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
    Xiong Z; Ohlfest JR
    J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
    Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
    Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus.
    Yokogawa M; Takaishi M; Nakajima K; Kamijima R; Fujimoto C; Kataoka S; Terada Y; Sano S
    Arthritis Rheumatol; 2014 Mar; 66(3):694-706. PubMed ID: 24574230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma.
    Smorlesi A; Papalini F; Orlando F; Donnini A; Re F; Provinciali M
    Gene Ther; 2005 Sep; 12(17):1324-32. PubMed ID: 15944732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer treatment with imiquimod: applying an old lotion to a new disease.
    Kohrt H
    Clin Cancer Res; 2012 Dec; 18(24):6571-3. PubMed ID: 23172886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
    Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
    Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
    Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
    J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
    Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
    Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effects of imiquimod on an animal model of asthma].
    Yin KS; Jin SX; Bian T; Wu QZ; Wang X; Yao X
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jul; 30(7):509-17. PubMed ID: 17961405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.